吉西他滨每周方案或联合奥沙利铂治疗老年肺癌

目的探讨吉西他滨单药或联合奥沙利铂每周方案治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法选择2009年10月至2012年10月在佛冈县人民医院就诊的48例老年NSCLC患者作为研究对象,按数字表随机法将患者分为吉西他滨单药组及吉西他滨联合奥沙利铂组,吉西他滨单药组给予吉西他滨单药每周方案,吉西他滨联合奥沙利铂组在吉西他滨单药组的基础上联合奥沙利铂治疗。治疗完成后对患者的生活质量、临床客观有效率(ORR)、疾病控制率(DCR)及毒性反应进行评价。结果两组患者治疗完成情况相当(χ2=0.181,P=0.671)。吉西他滨单药组患者生活质量好转情况与吉西他滨联合奥沙利铂组比较,差异有统计学意义(Z=2.272,P=0.023)。两组患者的客观有效率分别为17.4%、50.0%,疾病控制率为56.5%、83.3%,两组比较差异均有统计学意义(χ2=4.372,P=0.037;χ2=4.037,P=0.045)。两组患者的毒性反应相当,多为Ⅰ^Ⅱ度,比较差异无统计学意义(P>0.05)。结论吉西他滨联合奥沙利铂每周方案治疗老年晚期NSCLC的疗效优于吉西他滨单药,其近期疗效及安全性较好。

Study on Gemcitabine Weekly Therapy and Gemcitabine Combined with Oxaliplatin Therapy in the Treatment for Senile Lung Cancer

Objective To compare the curative effect and safety of gemcitabine weekly therapy and gemcitabine combined with oxaliplatin therapy in the treatment of non-small cell lung cancer （ NSCLC ） among elderly patients. Methods A total of 48 elderly patients with NSCLC treated in Fogang County people＇s Hospital from Oct. 2009 to Oct. 2012 were selected and divided into gemcitabine group and gemcitabine combined with oxaliplatin group according to random number table. Patients in gemcitabine group were only treated with gemcitabine weekly therapy,while patients in gemcitabine combined with oxaliplatin group were treated with gemcitabine and oxaliplatin. After treatment, the life quality, objective clinical response rate （ ORR）, disease control rate （DCR） and toxicity reactions of the two groups were evaluated. Results The completion status of treatment was equal between gemcitabine group and gemcitabine combined with oxaliplatin group（ χ2 =0. 181 ,P =0. 671 ）. The life quality of the two groups had significant statistical difference（ Z = 2. 272,P = 0. 023）. ORR and DCR of gemcitabine group were 17.4% and 56.5% respectively,while that of gemcitabine combined with oxaliplatin group were 50.0% and 83.3%, the difference of ORR and DCR between the two groups was statistically significant （ χ2 = 4.372,P = 0. 037 ; χ2 = 4.037, P = 0.045 ）. Toxicity reac- tions of the two groups were similar and most of the toxicity reactions belonged to grade Ito II,and there was no significant statistical difference（P 〉 0.05）. Conclusion Gemcitabine combined with oxaliplatin is superior to single gemcitabine therapy in the treatment of advanced senile NSCLC and has better recent curative effect and safety.